Tyumen', Russian Federation
graduate student
Tyumen, Tyumen, Russian Federation
Tyumen, Tyumen, Russian Federation
Tyumen, Tyumen, Russian Federation
UDC 616.31
Subject: Drug-induced oral mucositis is one of the most severe complications manifesting as lesions of the oral mucosa in patients undergoing chemotherapy. The prevalence of drug-induced oral mucositis when using chemotherapeutic agents ranges from 20% (with monotherapy) to 100% (with the simultaneous use of radiotherapy and chemotherapy). The analysis and systematization of factors contributing to the onset of drug-induced oral mucositis during chemotherapy are necessary to clarify their prognostic role. Objective: To identify and analyze the risk factors for the development of drug-induced oral mucositis during cytostatic therapy of oncological diseases, as described in scientific publications. Methodology: A content analysis of scientific literature was conducted in databases: PubMed, eLIBRARY, Google Scholar, and others, using predefined keywords. Publications were initially selected by title, date, and abstract. Further selection was based on availability of title, summary, and conclusions, followed by access to full texts. Results: Drug-induced oral mucositis is a serious complication of antitumor therapy, characterized by inflammation and ulceration of the oral mucosa against the background of chemotherapy. The data presented in the analyzed literature demonstrate a variety of risk factors for the occurrence of drug-induced oral mucositis. Three groups of risk factors were distinguished (patient status, tumor characteristics, treatment strategy). The possibility of various combinations of risk factors both within a single group and across groups is of particular interest for prognostic research. Conclusion: A more detailed study of risk factors will make it possible to predict the course, as well as to develop preventive measures and treatment strategies for drug-induced oral mucositis.
drug-induced oral mucositis, risk factors, chemotherapy, cytostatic therapy, complications of antitumor therapy
1. Dodd M. The pathogenesis and characterization of oral mucositis associated with cancer therapy. Oncology nursing forum. 2004;31(4 Suppl):5-11. https://doi.org/10.1188/04.ONF.S4.5-11
2. Romanenko I.G., Arakelyan K.A., Salischeva V.O. Sovremennye koncepcii profilaktiki i lecheniya oral'nogo mukozita pri onkoterapii. Vyatskiy medicinskiy vestnik. 2021;(1):96-101. [Romanenko I.G., Arakelyan K.A., Salishcheva V.O. Up-to-date concepts of prevention and treatment for oral mucositis in cancer therapy. Vâtskij medicinskij vestnik. 2021;(1):96-101. (In Russ.)]. https://elibrary.ru/item.asp?id=44882347
3. Bockel S., Vallard A., Lévy A., François S., Bourdis M., Le Gallic C. et al. Pharmacological modulation of radiation-induced oral mucosal complications. Cancer radiotherapie. 2018;22(5):429-437. https://doi.org/10.1016/j.canrad.2017.11.006. 29776830.
4. Fedorinov D.S., Geydarov R.N., Shashkov I.A., Mihaylovich V.M., Lyadova M.A., Pokataev I.A. i dr. Farmakogeneticheskie markery toksichnosti himioterapii opuholey zheludochno-kishechnogo trakta: predvaritel'nyy analiz. Sovremennaya onkologiya. 2021;23(2):314-318. [Fedorinov D.S., Geidarov R.N., Shashkov I.A., Mikhailovich V.M., Lyadova M.A., Pokataev I.A. et al. Pharmacogenetic markers of chemotherapy toxicity in gastrointestinal tumors: a preliminary analysis. Journal of Modern Oncology. 2021;23(2):314-318. (In Russ.)]. https://doi.org/10.26442/18151434.2021.2.200890
5. Cario E. Toll-like receptors in the pathogenesis of chemotherapy-induced gastrointestinal toxicity. Current opinion in supportive and palliative care. 2016;10(2):157-164. https://doi.org/10.1097/SPC.0000000000000202
6. Al-Rudayni A.H.M., Gopinath D., Maharajan M.K., Menon R.K. Impact of oral mucositis on quality of life in patients undergoing oncological treatment: a systematic review. Translational cancer research. 2020;9(4):3126-3134. https://doi.org/10.21037/tcr.2020.02.77
7. Valeh M., Kargar M., Mansouri A., Kamranzadeh H., Gholami K., Heidari K. et al. Factors Affecting the Incidence and Severity of Oral Mucositis Following Hematopoietic Stem Cell Transplantation. International journal of hematology-oncology and stem cell research. 2018;12(2):142-152. https://pmc.ncbi.nlm.nih.gov/articles/PMC6141433/
8. Bowen J.M., Wardill H.R. Advances in the understanding and management of mucositis during stem cell transplantation. Current opinion in supportive and palliative care. 2017;11(4):341-346. https://doi.org/10.1097/SPC.0000000000000310
9. Semiglazova T.Yu., Belyak N.P., Vladimirova L.Yu., Kornieckaya A.L., Koroleva I.A., Nechaeva M.N. i dr. Prakticheskie rekomendacii po lecheniyu i profilaktike mukozitov. Zlokachestvennye opuholi. 2021;11(3s2-2):224-232. [Semiglazova T.Yu., Belyak N.P., Vladimirova L.Yu., Kornieetskaya A.L., Koroleva I.A., Nechaeva M.N. et al. Practical recommendations for the treatment and prevention of mucositis. Malignant Tumors. 2021;11(3s2-2):224-232. (In Russ.)]. https://doi.org/10.18027/2224-5057-2021-11-3s2-51
10. Kusiak A., Jereczek-Fossa B.A., Cichońska D., Alterio D. Oncological-Therapy Related Oral Mucositis as an Interdisciplinary Problem-Literature Review. International journal of environmental research and public health. 2020;17(7):2464. https://doi.org/10.3390/ijerph17072464
11. Boris S.P. Faktory riska, medicinskaya profilaktika i lechenie oral'nogo mukozita u detey s onkogematologicheskimi zabolevaniyami: avtoref. dis. ... k.m.n. Minsk; 2018. 23 s. [Boris S.P. Risk Factors, Medical Prevention, and Treatment of Oral Mucositis in Children with Oncohematological Diseases: master‘s thesis. Minsk; 2018. 23p. (In Russ.)]. https://rusneb.ru/catalog/000199_000009_009556453/
12. Campos M.I., Campos C.N., Aarestrup F.M., Aarestrup B.J. Oral mucositis treatment: natural history, prevention and treatment. Molecular and clinical oncology. 2014;2(3):337-340. https://doi.org/10.3892/mco.2014.253
13. Galloway T., Amdur R. Management and prevention of complications during treatment of head and neck cancer. This topic last updated: Aug 01, 2024. UpTo Date, Waltham, MA. Available from: https://www.uptodate.com/contents/3408.
14. Makeeva I.M., Komogorceva V.E., Reshetov I.V., Margaryan E.G., Put' V.A., Kadzhoyan A.G. Stomatologicheskiy status pacientov, gotovyaschihsya k himioterapevticheskomu lecheniyu po povodu onkologicheskih zabolevaniy. Medicinskiy alfavit. 2022;(22):32-37. [Makeeva I.M., Komogortseva V.E., Reshetov I.V., Margaryan E.G., Put V.A., Kadzhoyan A.G. Oral status of patients in need of cancer chemotherapy. Medical alphabet. 2022;(22):32-37. (In Russ.)]. https://doi.org/10.33667/2078-5631-2022-22-32-37
15. Gutierrez-Camino A., Oosterom N., den Hoed M.A.H., Lopez-Lopez E., Martin-Guerrero I., Pluijm S.M.F. et al. The miR-1206 microRNA variant is associated with methotrexate-induced oral mucositis in pediatric acute lymphoblastic leukemia. Pharmacogenetics and genomics. 2017;27(8):303-306. https://doi.org/10.1097/FPC.0000000000000291.
16. Garneau A.P., Riopel J., Isenring P. Acute Methotrexate-Induced Crystal Nephropathy. The New England journal of medicine. 2015;373(27):2691-2693. https://doi.org/10.1056/NEJMc1507547.
17. Hu Z., Escalera-Joy A.M., Ashcraft E., Acharya R., Jeha S., Cheng C. et al. Clinical Risk Factors for High-Dose Methotrexate-Induced Oral Mucositis Following Individualized Dosing. Cancer medicine. 2024;13(21):e70351. https://doi.org/10.1002/cam4.70351
18. Misaka K.O., Suga Y., Staub Y., Tsubata A., Shimada T., Sai Y. et al. Risk Factors for Delayed Elimination of Methotrexate in Children, Adolescents and Young Adults With Osteosarcoma. In vivo (Athens, Greece). 2020;34(6):3459-3465. https://doi.org/10.21873/invivo.12185
19. Valer J.B., Curra M., Gabriel A.F., Schmidt T.R., Ferreira M.B.C., Roesler R., et al. Oral mucositis in childhood cancer patients receiving high-dose methotrexate: Prevalence, relationship with other toxicities and methotrexate elimination. International journal of paediatric dentistry. 2021;31(2):238-246. https://doi.org/10.1111/ipd.12718.
20. Roth J.A., Kaeberle M.L., Hsu W.H. Effect of estradiol and progesterone on lymphocyte and neutrophil functions in steers. Infection and immunity. 1982;35(3):997-1002. https://doi.org/10.1128/iai.35.3.997-1002.1982
21. Damascena L.C.L., De Lucena N.N.N., Ribeiro I.L.A., De Araujo T.L.P., De Castro R.D., Bonan P.R.F. et al. Factors Contributing to the Duration of Chemotherapy-Induced Severe Oral Mucositis in Oncopediatric Patients. International journal of environmental research and public health. 2018;15(6):1153. https://www.sci-hub.ru/10.3390/ijerph17041235
22. Wardill H.R., Sonis S.T., Blijlevens N.M.A., Van Sebille Y.Z.A., Ciorba M.A., Loeffen E.A.H. et al. Prediction of mucositis risk sec-ondary to cancer therapy: a systematicreview of current evidence and call to ac-tion. Supportive care in cancer. 2020;28:5059-5073. https://doi.org/10.1007/s00520-020-05579-7
23. Shouval R., Kouniavski E., Fein J., Danylesko I., Shem-Tov N., Geva M. et al. Risk factors and implications of oral mucositis in recipients of allogeneic hematopoietic stem cell transplantation. European journal of haematology. 2019;103(4):402-409. https://doi.org/10.1111/ejh.13299
24. Çakmak S., Nural N. Incidence of and risk factors for development of oral mucositis in outpatients undergoing cancer chemotherapy. International journal of nursing practice. 2019;25(1):e12710. https://doi.org/10.1111/ijn.12710
25. Villa A., Sonis S.T. Pharmacotherapy for the management of cancer regimenrelated oral mucositis. Expert opinion on pharmacotherapy. 2016;17:1801–1807. https://doi.org/10.1080/14656566.2016.1217993
26. de Farias Gabriel A., Silveira F.M., CurraM., Schuch L.F., Wagner V.P., Martins M.A.T. et al. Risk factors associated with thedevelopment of oral mucositis in pediat-ric oncology patients: systematic reviewand meta- analysis. Oral diseases. 2022;28(4):1068-1084. https://doi.org/10.1111/odi.13863
27. Cancer related mucositis management. – Gippsland Oncology Nurses Group, 2007. – 40 p. https://www.yumpu.com/en/document/view/21413070/cancer-related-mucositis-management
28. Peterson D.E., Boers-Doets C.B., Bensadoun R.J., Herrstedt J. Management of oral and gastrointestinal mucosal injury: ESMO Clinical Practice Guidelines for diagnosis, treatment, and follow-up. Annals of oncology. 2015;26(suppl. 5):139–151. https://doi.org/10.1093/annonc/mdv202.
29. Singh V., Singh A.K. Oral mucositis. National journal of maxillofacial surgery. 2020;11(2):159-168. https://doi.org/10.4103/njms.NJMS_10_20
30. Mendonça R.M., de Araújo M., Levy C.E., Morari J., Silva R.A., Yunes J.A. et al. Oral Mucositis in Pediatric Acute Lymphoblastic Leukemia Patients: Evaluation of Microbiological and Hematological Factors. Pediatric hematology and oncology. 2015;32(5):322-30. https://doi.org/10.3109/08880018.2015.1034819.
31. Semin D.Yu., Medvedev V.S., Mardynskiy Yu.S., Gulidov I.A., Isaev P.A., Radzhapova M.U. i dr. Organosohrannaya himioluchevaya terapiya raka slizistoy obolochki polosti rta i rotoglotki. Opuholi golovy i shei. 2011;(4):15-19. [Semin D.Yu., Medvedev V.S., Mardynsky Yu.S., Gulidov I.A., Isayev P.A., Radzhapova M.U. et al. Organ-sparing chemoradiotherapy for cancer of the oral and oropharyngeal mucosa. Head and neck tumors. 2011;(4):15-19. (In Russ.)]. https://elibrary.ru/item.asp?id=17055581
32. Sobue T., Bertolini M., Thompson A., Peterson D.E., Diaz P.I., Dongari-Bagtzoglou A. Chemotherapy-induced oral mucositis and associated infections in a novel organotypic model. Molecular oral microbiology. 2018;33(3):212-223. https://doi.org/10.1111/omi.12214
33. Haverman T.M., Laheij A.M.G.A., Nie M., Deng D.M., Raber-Durlacher J.E., de Soet J.J. et al. Exploring the role of oral microorganisms in the pathogenesis of mucositis by assessing their impact on metabolic activity and reproductive capacity of epithelial cells in vitro. Support Care Cancer. 2020;28(10):4729-4735. https://doi.org/10.1007/s00520-020-05318-y
34. Zav'yalov A.A., Tyryshkin A.I., Olesova V.N., Paschenko N.A., Gurkova M.M. Mesto i rol' mikroflory polosti rta v patogeneze oral'nogo mukozita pri zlokachestvennyh novoobrazovaniyah (obzor literatury). Sovremennaya onkologiya. 2023;25(4):525–530. [Zavyalov A.A., Tyryshkin A.I., Olesova V.N., Pashchenko N.A., Gurkova M.M. The place and role of oral microflora in the pathogenesis of oral mucositis in malignant neoplasms (literature review). Journal of Modern Oncology. 2023;25(4):525–530. (In Russ.)]. https://doi.org/10.26442/18151434.2023.4.202544
35. Aradya A., Kiran P.K., Raghavendra Swamy K.N., Doddawad V.G., Ranganatha N., Sravani K. Oral Risk Factors in Patients with Cancer Undergoing Chemotherapy - A Pilot Study. Indian journal of dental research. 2024;35(2):126-130. https://doi.org/10.4103/ijdr.ijdr_516_23
36. Saunders D.P., Epstein J.B., Elad S., Allemano J., Bossi P., van de Wetering M.D. et al. Systematic review ofantimicrobials, mucosal coating agents, anesthetics, and analgesicsfor the management of oral mucositis in cancer patients. Supportive care in cancer. 2013;21(11):3191–3207. https://doi.org/10.1007/s00520-013-1871-y
37. Mortensen H.R., Overgaard J., Jensen K., Specht L., Overgaar, M., Johanse, J. et al. Factors associated with acute and late dysphagia in the DAHANCA 6 & 7 randomized trial with accelerated radiotherapy for head and neck cancer. Acta oncologica (Stockholm, Sweden). 2013;52(7):1535-1542. https://doi.org/10.3109/0284186X.2013.824609
38. Damascena L.C.L., De Lucena N.N.N., Ribeiro I.L.A., De Araujo T.L.P., De Castro R.D., Bonan P.R.F. et al. Factors Contributing to the Duration of Chemotherapy-Induced Severe Oral Mucositis in Oncopediatric Patients. International journal of environmental research and public health. 2018;15(6):1153. https://doi.org/10.3390/ijerph15061153
